Peer-reviewed veterinary case report
Fluralaner oral and topical treatment for sarcoptic mange in dogs
By Chiummo, Rafael et al.·Published in Parasites & vectors·2020·MSD Animal Health Innovation GmbH, Germany·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Efficacy of orally and topically administered fluralaner (Bravecto) for treatment of client-owned dogs with sarcoptic mange under field conditions.
- Species:
- dog
Plain-English summary
A group of dogs with sarcoptic mange, which causes severe itching and skin problems, were treated with either oral or topical fluralaner (Bravecto) to eliminate the mites. After just one treatment, over 90% of the dogs were free of mites by Day 28, and by Day 84, all dogs had no signs of infestation or skin issues. The treatments were safe, with no side effects reported. This study shows that fluralaner is an effective option for treating sarcoptic mange in dogs.
People also search for: dog itching treatment · sarcoptic mange in dogs · Bravecto for dog mites · how to treat dog skin problems
Abstract
BACKGROUND: Successful canine sarcoptic mange treatment requires immediate efficacy to eliminate active mites, and sustained activity to prevent re-infestation from in-contact animals and fomites. With extended acaricidal activity, fluralaner has been shown to be effective for treating this disease. To confirm this potential under field conditions, two fluralaner formulations were administered to mite-infested, client-owned dogs. METHODS: Households qualified for inclusion if they had at least one dog positive for Sarcoptes scabiei mites, confirmed by skin scraping, and at least one dog with clinical signs evocative of sarcoptic mange. Households were allocated to groups of dogs to receive a single treatment with either oral (Bravectochewable tablets, MSD Animal Health) or topical (BravectoSpot-on, MSD Animal Health), fluralaner at a dose of ≥ 25 mg/kg (range 25-56 mg/kg) on Day 0, or two treatments with oral sarolaner (Simparicatablets, Zoetis) (Days 0 and 28) at ≥ 2 mg/kg (2-4 mg/kg). All dogs in each household were treated with the same product. On the enrolment day and subsequently on Days 28, 56 and 84, deep skin scrapings were taken from at least five different body areas judged to be most likely to have active mite infestation. At each visit, the dog's mange-associated skin lesions were recorded, and pruritus level was assessed. RESULTS: There were 98 participating households and 135 dogs enrolled across Albania, France, Italy and Portugal. On Day 28, more than 90% of dogs in each group were negative for mites. On Days 56 and 84, all study dogs were free of mites and most dermatological signs of sarcoptic mange had resolved. There were no treatment-related adverse events in any group. CONCLUSIONS: A single treatment of client-owned, sarcoptic mange-affected dogs with either fluralaner chewable tablets or fluralaner spot-on formulation proved a safe and effective treatment of infestations with S. scabiei var. canis, maintained through 84 days (12 weeks) after treatment.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/33069261/